An oral, chemotherapy‐free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia

Chemotherapy with the use of next‐generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia

“…39 All 53 patients achieved CR. Our group adopted this oral chemotherapy-free treatment regimen for 13 adult patients, 53 and the high CR and MMR rates and better quality of life during the treatment suggest that using chemotherapy-free regimens is promising. Encouragingly, the bispecific T-cell engager anti-CD3 and CD19 antibody blinatumomab was incorporated into a chemotherapy-free protocol of dasatinib plus steroids, leading to a dramatic improvement in the form of a high molecular response rate and an impressive 18-month survival rate.…”

Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia: A single‐arm, multicentre, phase 2 trial

“…6,7 Previously, we retrospectively analysed a single-centre cohort of 13 patients treated with dasatinib and prednisone as induction regimen, determining the oral, chemo-free regimen yields 100% of CR rates in Ph + ALL with minimal induction death. 8 To further investigate the efficacy of dasatinib plus prednisone as an introduction and early consolidation therapy in Ph + ALL, we present a prospective, multicentre, single-arm study of Ph + ALL treatment using induction and consolidation treatment with dasatinib and prednisone followed by allogeneic HSCT, autologous HSCT or chemotherapy based on donor availability and patient age. The survival of patients with or without transplantation at first remission was also compared to determine the role and need of transplantation in this protocol.…”

“…More recently, a CD3–CD19 bispecific antibody, blinatumomab, incorporating with newer‐generation TKIs as both induction and consolidation therapy achieved higher rates of deep molecular response (a CMR, complete molecular remission of 87% in ponatinib with blinatumomab) and better survival benefits (a 18‐months OS, overall survival of 88% in dasatinib with blinatumomab), further shifting Ph + ALL treatment strategies towards chemotherapy‐free regimen 6,7 . Previously, we retrospectively analysed a single‐centre cohort of 13 patients treated with dasatinib and prednisone as induction regimen, determining the oral, chemo‐free regimen yields 100% of CR rates in Ph + ALL with minimal induction death 8 . To further investigate the efficacy of dasatinib plus prednisone as an introduction and early consolidation therapy in Ph + ALL, we present a prospective, multicentre, single‐arm study of Ph + ALL treatment using induction and consolidation treatment with dasatinib and prednisone followed by allogeneic HSCT, autologous HSCT or chemotherapy based on donor availability and patient age.…”